Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
This project is supported by the Irish Government through IDA Ireland
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Morepen Labs successfully raised Rs. 200 Crore through QIP
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Subscribe To Our Newsletter & Stay Updated
